Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Khora Spv 1 LLC is currently navigating the patent prosecution process with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to 1 distinct examiner and is being processed within 1 distinct art unit. The data shows that the company's current interactions with the USPTO are limited to this technical and administrative channel.
The busiest examiner for the company is FETTEROLF, BRANDON J, who is currently managing 1 busiest examiner pending office action. Since this count is the same as the total number of pending office actions, this individual is responsible for the company's entire active workload at the patent office. The reliance on the assigned official means that the immediate patenting outcomes are subject to the specific scrutiny of this individual within the Biotechnology & Pharmaceuticals sector.
For patent practitioners, the involvement of only the distinct art unit provides a specific environment for prosecution strategy. The presence of the assigned examiner means there is no current opportunity to compare examiner behaviors across different matters for this applicant. Success in the current cycle depends on addressing the concerns raised in the pending office action, as it represents the company's current footprint at the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717390 | SOLID STATE FORMS OF AN FGFR INHIBITOR | FETTEROLF, BRANDON J | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717390 | SOLID STATE FORMS OF AN FGFR INHIBITOR | FETTEROLF, BRANDON J | 1626 | §102DP | Non-Final OA | — | Pending | Jun 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKhora Spv 1 LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brandon J Fetterolf has the most, with 1 of Khora Spv 1 LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
